Compare TFPM & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFPM | HAE |
|---|---|---|
| Founded | 2016 | 1971 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.4B |
| IPO Year | 2022 | 1996 |
| Metric | TFPM | HAE |
|---|---|---|
| Price | $27.74 | $120.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $39.25 | ★ $147.18 |
| AVG Volume (30 Days) | 404.0K | ★ 557.4K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.72 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | $26.92 | $8.17 |
| Revenue Next Year | $17.67 | $10.82 |
| P/E Ratio | ★ $35.57 | $70.92 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.61 | $51.00 |
| 52 Week High | $41.70 | $132.00 |
| Indicator | TFPM | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 51.45 |
| Support Level | $27.21 | $116.09 |
| Resistance Level | $31.86 | $122.84 |
| Average True Range (ATR) | 1.00 | 4.86 |
| MACD | -0.20 | -0.56 |
| Stochastic Oscillator | 0.28 | 20.95 |
Triple Flag Precious Metals Corp is a streaming and royalty company focused on precious metals. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Mexico, Mongolia, Peru, South Africa, and the United States. Its diversified portfolio of streams and royalties comprises long-life mining assets, including the Northparkes copper-gold mine in Australia, the Cerro Lindo polymetallic mine in Peru, the Fosterville gold mine in Australia, the Buritica gold mine in Colombia, and the Impala Bafokeng Operations in South Africa among others. A majority of its revenue is derived through its interests in various gold streams. Geographically, the company derives maximum revenue from Australia, followed by Peru and other regions.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.